#	Pagina
attuale pagina	/open-h2020/projects/204372/index.html
-1	/open-h2020/projects/218004/index.html
-2	/open-h2020/projects/208707/index.html
-3	/open-h2020/per-topic/leon/list/index.html
-4	/open-h2020/per-topic/dfss/list/index.html
-5	/open-h2020/per-topic/evolift/list/index.html
-6	/open-fp7/projects/106703/index.html
-7	/open-h2020/per-topic/introductory/list/index.html
-8	/open-h2020/projects/194435/index.html
-9	/open-h2020/projects/221599/index.html
-10	/open-h2020/projects/213253/index.html

Opendata, web and dolomites

SAP-Nano

A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

SAP-Nano project word cloud

Explore the words cloud of the SAP-Nano project. It provides you a very rough idea of what is the project "SAP-Nano" about.

swine suitable solved volatile patented issue time evaluation perform seemed nanotechnology veterinary viability industrial strategies ensures 11 performed impossible detected standard solvents point usd molecules plan successfully inexpensive market 2015 economic nanoparticle manufacturers commercial sap antigens thorough instrument techniques laboratory encapsulate firstly billion requirement minimize launch fish avoiding vaccines nmp conventional prrsv scalability company industry million costly manufacturer nano met presented marketing eur verify 25 scalable 664 significantly score easily opportunity submission pharmaceutical 84 cosmetic first manufacturing risks faced clients business versatile usa 21 bionanoplus move losses feasibility model lower 12 total organic sme

Project "SAP-Nano" data sheet

The following table provides information about the project.

Coordinator	BIONANOPLUS SL Organization address address: POLIGONO MOCHOLI, PLAZA CEIN 5 city: NOAIN postcode: 31110 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.bionanoplus.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2016-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BIONANOPLUS SL BIONANOPLUS SL Organization address address: POLIGONO MOCHOLI, PLAZA CEIN 5 city: NOAIN postcode: 31110 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (NOAIN)	coordinator	50˙000.00

Map

Project objective

Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology. It seemed impossible and costly to move a product developed in the laboratory to the industrial manufacturing of the product. To solve this issue Bionanoplus has developed and patented a highly versatile and easily scalable technology to encapsulate antigens and other molecules, called SAP-Nano. Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques. SAP-Nano technology has been successfully implemented with two clients, a fish vaccines manufacturer and a pharmaceutical company. Now Bionanoplus plan to launch his technology in the vaccines manufacturers market, firstly on to the PRRSV vaccines manufacturers market. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA. SAP-Nano enables the development of unique vaccines, which are significantly more effective than conventional vaccines. Phase 1 of SME Instrument represents an opportunity to get a thorough business plan to minimize risks. The main objective is to perform a feasibility study to verify the economic viability in the vaccines manufacturers market and design a suitable business model, and the commercial, marketing and industrial strategies. The SAP-Nano proposal was presented for the first time to the 25-11-2015 call (NMP-25-2015-1-P) achieving a total score of 12,84. The lower point in the evaluation was Impact (score: 4.21). B has met potential clients in order to know the needs and requirement to develop new vaccines. The business case has also been improved. This new information has been included in this new submission of the proposal.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAP-NANO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAP-NANO" are provided by the European Opendata Portal: CORDIS opendata.